Leonard, John P

Publications

Sort by

Co-Author Network

selected publications

Subclonal TP53 mutation are frequent and predict resistance to radio-immunotherapy in follicular lymphoma. Blood advances. 2023 Academic Article GET IT
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood advances. 2023 Academic Article GET IT
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. European heart journal. 2023 Academic Article GET IT
Times cited: 20
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?. Haematologica. 2023 Academic Article GET IT
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 Academic Article GET IT
Times cited: 5
Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis. Cancer medicine. 2023 Academic Article GET IT
Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica. 2022 Academic Article GET IT
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Academic Article GET IT
Times cited: 192
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 4
Unmet mental health needs in patients with advanced B-cell lymphomas. Palliative & supportive care. 2022 Academic Article GET IT
Times cited: 2
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood advances. 2022 Academic Article GET IT
POD24 in follicular lymphoma: time to be "wise". Blood. 2022 Editorial Article GET IT
Times cited: 1
An architecture for research computing in health to support clinical and translational investigators with electronic patient data. Journal of the American Medical Informatics Association : JAMIA. 2022 Academic Article GET IT
Times cited: 3
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 2022 Academic Article GET IT
Times cited: 13
Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma Patients. Clinical lymphoma, myeloma & leukemia. 2022 Academic Article GET IT
Times cited: 1
Racial Disparities in Diabetes-Related Emergency Department Visits and Hospitalizations Among Cancer Survivors. JCO oncology practice. 2022 Academic Article GET IT
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. The Lancet. Haematology. 2021 Academic Article GET IT
Times cited: 8
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. Cancer research. 2021 Academic Article GET IT
Times cited: 8
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. 2021 GET IT
Times cited: 6
Serologic response to mRNA COVID-19 vaccination in lymphoma patients. American journal of hematology. 2021 Letter GET IT
Times cited: 22
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone marrow transplantation. 2021 Academic Article GET IT
Times cited: 13
Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study. Clinical lymphoma, myeloma & leukemia. 2021 Academic Article GET IT
Times cited: 3
An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2021 Academic Article GET IT
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. American journal of hematology. 2021 Academic Article GET IT
Times cited: 9
Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 2
Racial disparities in diabetes care among incident breast, prostate, and colorectal cancer survivors: a SEER Medicare study. Journal of cancer survivorship : research and practice. 2021 Academic Article GET IT
Times cited: 4
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. The American journal of surgical pathology. 2021 Academic Article GET IT
Times cited: 8
Laboratory Workup of Lymphoma in Adults: Guideline From the American Society for Clinical Pathology and the College of American Pathologists. 2021 GET IT
Times cited: 7
Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset. Leukemia & lymphoma. 2021 Academic Article GET IT
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 48
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer discovery. 2021 Academic Article GET IT
Times cited: 68
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021 Academic Article GET IT
Times cited: 49
Laboratory Workup of Lymphoma in Adults. 2021 GET IT
Times cited: 10
Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leukemia & lymphoma. 2020 Academic Article GET IT
Times cited: 22
Mantle Cell Lymphoma: Biologic Insights to Bedside Impact. Hematology/oncology clinics of North America. 2020 Editorial Article GET IT
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA: a cancer journal for clinicians. 2020 Academic Article GET IT
Times cited: 12
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 47
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020 Academic Article GET IT
Times cited: 43
Lenalidomide in follicular lymphoma. Blood. 2020 Review GET IT
Times cited: 13
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. The Lancet. Haematology. 2020 Academic Article GET IT
Times cited: 10
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia & lymphoma. 2020 Academic Article GET IT
Times cited: 1
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. American journal of hematology. 2020 Academic Article GET IT
Times cited: 17
Diabetes care management patterns before and after a cancer diagnosis: A SEER-Medicare matched cohort study. Cancer. 2020 Academic Article GET IT
Times cited: 23
Lymphoma Study Titles on ClinicalTrials.gov Lack Details Necessary for Study Identification. Clinical lymphoma, myeloma & leukemia. 2019 Academic Article GET IT
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood advances. 2019 Academic Article GET IT
Times cited: 17
Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma. Journal of palliative medicine. 2019 Academic Article GET IT
Times cited: 4
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 64
Reply to T.M. Weis et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Comment GET IT
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 84
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. 2019 Academic Article GET IT
Times cited: 7
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 18
Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2019 Academic Article GET IT
De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Editorial Article GET IT
Times cited: 3
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 208
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 197
Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). British journal of haematology. 2019 Academic Article GET IT
Times cited: 8
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019 Academic Article GET IT
Times cited: 30
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 77
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 50
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 8
Establishing the Feasibility of a Tablet-Based Consent Process with Older Adults: A Mixed-Methods Study. The Gerontologist. 2019 Academic Article GET IT
Times cited: 11
New developments in the treatment of follicular lymphoma. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2019 Review GET IT
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. Cancer medicine. 2018 Academic Article GET IT
Times cited: 26
Novel immunotherapy approaches to follicular lymphoma. Hematology. American Society of Hematology. Education Program. 2018 Review GET IT
Times cited: 5
Sequencing of therapies in relapsed follicular lymphoma. Hematology. American Society of Hematology. Education Program. 2018 Review GET IT
Times cited: 8
Where to start? Upfront therapy for follicular lymphoma in 2018. Hematology. American Society of Hematology. Education Program. 2018 Review GET IT
Times cited: 5
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood. 2018 Academic Article GET IT
Times cited: 28
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
DLBCL Cell of Origin: What Role Should It Play in Care Today?. Oncology (Williston Park, N.Y.). 2018 Review GET IT
Times cited: 16
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 69
Management of Relapsed and Refractory Hodgkin Lymphoma in 2018. JAMA oncology. 2018 Academic Article GET IT
Times cited: 1
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018 Academic Article GET IT
Times cited: 68
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. Blood advances. 2018 Review GET IT
Times cited: 8
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. HemaSphere. 2018 Academic Article GET IT
Times cited: 9
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). Journal of geriatric oncology. 2018 Academic Article GET IT
Times cited: 5
Secondary Use of Patients' Electronic Records (SUPER): An Approach for Meeting Specific Data Needs of Clinical and Translational Researchers. AMIA ... Annual Symposium proceedings. AMIA Symposium. 2018 Academic Article GET IT
Times cited: 36
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1068
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica. 2018 Letter GET IT
Times cited: 19
Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee. British journal of haematology. 2018 Letter GET IT
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 51
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. British journal of haematology. 2017 Letter GET IT
Times cited: 3
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 64
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. British journal of haematology. 2017 Academic Article GET IT
Times cited: 91
Lymphoma "benchmark" or "bench-smudge"?. Blood. 2017 Comment GET IT
Times cited: 7
The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. 2017 Review GET IT
Times cited: 9
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 117
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials. British journal of haematology. 2017 Academic Article GET IT
Times cited: 10
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Conference Paper GET IT
Times cited: 195
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Review GET IT
Times cited: 50
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 6
The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval. Oncology (Williston Park, N.Y.). 2017 Editorial Article GET IT
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. British journal of haematology. 2017 Academic Article GET IT
Times cited: 25
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. The Lancet. Haematology. 2017 Academic Article GET IT
Times cited: 68
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer discovery. 2017 Academic Article GET IT
Times cited: 34
Phase-locking behavior in a high-frequency gymnotiform weakly electric fish, Adontosternarchus. Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology. 2017 Academic Article GET IT
Times cited: 1
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. Journal of the National Cancer Institute. 2016 Review GET IT
Times cited: 24
Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute. 2016 Review GET IT
Times cited: 20
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute. 2016 Review GET IT
Times cited: 11
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute. 2016 Review GET IT
Times cited: 22
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. British journal of haematology. 2016 Academic Article GET IT
Times cited: 38
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. Journal of the National Cancer Institute. 2016 Review GET IT
Times cited: 49
General Biomarker Recommendations for Lymphoma. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 1
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet. Haematology. 2016 Academic Article GET IT
Times cited: 30
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. Blood advances. 2016 Academic Article GET IT
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016 Academic Article GET IT
Times cited: 44
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 110
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical epigenetics. 2016 Academic Article GET IT
Times cited: 35
Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. Cell cycle (Georgetown, Tex.). 2016 Academic Article GET IT
Times cited: 5
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. British journal of haematology. 2016 Academic Article GET IT
Times cited: 24
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 201
Lenalidomide plus Rituximab for Mantle-Cell Lymphoma. The New England journal of medicine. 2016 Letter GET IT
Times cited: 4
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget. 2016 Academic Article GET IT
Times cited: 25
Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 191
CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2016 Academic Article GET IT
Times cited: 3
Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2015 Academic Article GET IT
Times cited: 9
Idelalisib-associated Colitis: Histologic Findings in 14 Patients. The American journal of surgical pathology. 2015 Academic Article GET IT
Times cited: 107
Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia. 2015 GET IT
Times cited: 6
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 182
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 34
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 140
Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015 Academic Article GET IT
Times cited: 27
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 112
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 16
A roadmap for discovery and translation in lymphoma. Blood. 2015 Letter GET IT
Times cited: 17
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 13
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 212
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 9
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 64
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 Academic Article GET IT
Times cited: 189
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. British journal of haematology. 2014 Academic Article GET IT
Times cited: 70
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2013 Academic Article GET IT
Times cited: 62
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2013 Academic Article GET IT
Times cited: 154
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 12
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 75
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer discovery. 2013 Academic Article GET IT
Times cited: 149
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer. 2013 Academic Article GET IT
Times cited: 50
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell cycle (Georgetown, Tex.). 2013 Academic Article GET IT
Times cited: 2040
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013 Academic Article GET IT
Times cited: 69
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. Hematology. American Society of Hematology. Education Program. 2013 Review GET IT
Times cited: 22
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 23
Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?. Clinical advances in hematology & oncology : H&O. 2012 Academic Article GET IT
Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 65
Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology (Amsterdam, Netherlands). 2012 Academic Article GET IT
Times cited: 18
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 Academic Article GET IT
Times cited: 256
Comparing decision making between cancer patients and the general population: thoughts, emotions, or social influence?. Journal of health communication. 2012 Academic Article GET IT
Times cited: 12
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. American journal of hematology. 2012 Letter GET IT
Times cited: 33
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 55
Splenic lymphomas: is there still a role for splenectomy?. Oncology (Williston Park, N.Y.). 2012 Comment GET IT
Times cited: 2
Targeting CD30 in hodgkin lymphoma: antibody-drug conjugates make a difference. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2012 Academic Article GET IT
A worrisome interventricular septum: more than meets the eye. 2011 GET IT
Times cited: 1
Is there a role for "watch and wait" in patients with mantle cell lymphoma?. Seminars in hematology. 2011 Review GET IT
Times cited: 22
Advancing through maintenance in mantle cell lymphoma. Leukemia & lymphoma. 2011 Comment GET IT
Toxicity burden score: a novel approach to summarize multiple toxic effects. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 39
Pilot study of Aurora, a social, mobile-phone-based emotion sharing and recording system. Journal of diabetes science and technology. 2011 Academic Article GET IT
Times cited: 28
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011 Academic Article GET IT
Times cited: 163
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 278
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukemia & lymphoma. 2010 Review GET IT
Times cited: 20
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet. Oncology. 2010 Academic Article GET IT
Times cited: 622
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. The New England journal of medicine. 2010 Academic Article GET IT
Times cited: 1107
Management of mantle cell lymphoma: key challenges and next steps. Clinical lymphoma, myeloma & leukemia. 2010 Review GET IT
Times cited: 10
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American journal of hematology. 2010 Academic Article GET IT
Times cited: 45
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 46
Motivation for health information seeking and processing about clinical trial enrollment. Health communication. 2010 Academic Article GET IT
Times cited: 64
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 52
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical lymphoma, myeloma & leukemia. 2010 Academic Article GET IT
Times cited: 45
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 45
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 140
Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Clinical advances in hematology & oncology : H&O. 2010 Academic Article GET IT
Times cited: 5
Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Clinical advances in hematology & oncology : H&O. 2010 Academic Article GET IT
Times cited: 1
Individuals' willingness to talk to their doctors about clinical trial enrollment. Journal of health communication. 2010 Academic Article GET IT
Times cited: 26
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. Leukemia & lymphoma. 2010 Conference Paper GET IT
Times cited: 5
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Review GET IT
Times cited: 50
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 43
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Academic Article GET IT
Times cited: 231
Novel agents for follicular lymphoma. Hematology. American Society of Hematology. Education Program. 2010 Academic Article GET IT
Times cited: 8
Reality of complementary and alternative medicine in lymphoma patients: hope, hype, or help?. American journal of hematology. 2009 Editorial Article GET IT
Times cited: 1
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2009 Academic Article GET IT
Times cited: 625
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 659
Repeated courses of rituximab in chronic ITP: Three different regimens. American journal of hematology. 2009 Academic Article GET IT
Times cited: 61
From information processing to behavioral intentions: exploring cancer patients' motivations for clinical trial enrollment. Patient education and counseling. 2009 Academic Article GET IT
Times cited: 45
Mantle cell lymphoma: biological insights and treatment advances. Clinical lymphoma & myeloma. 2009 Review GET IT
Times cited: 19
Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park, N.Y.). 2009 Review GET IT
Times cited: 16
Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. 2009 GET IT
Times cited: 4
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British journal of haematology. 2009 Academic Article GET IT
Times cited: 216
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 146
Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma. Leukemia & lymphoma. 2009 Comment GET IT
Times cited: 8
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 286
Antibody treatment in lymphoma. Clinical advances in hematology & oncology : H&O. 2009 Academic Article GET IT
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert opinion on investigational drugs. 2009 Review GET IT
Times cited: 19
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Review GET IT
Times cited: 89
Progress in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Editorial Article GET IT
Times cited: 19
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 289
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008 Academic Article GET IT
Times cited: 101
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 43
FDG-PET scans in patients with lymphoma. Current hematologic malignancy reports. 2008 Academic Article GET IT
Times cited: 1
New biologic agents and immunologic strategies. Hematology/oncology clinics of North America. 2008 Review GET IT
Times cited: 6
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. The New England journal of medicine. 2008 Review GET IT
Times cited: 380
Concomitant diffuse large B-cell lymphoma and hepatocellular carcinoma in chronic hepatitis C virus liver disease: a study of two cases. 2008 GET IT
Times cited: 16
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia. 2008 Academic Article GET IT
Times cited: 53
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 100
Targeted treatment and new agents in diffuse large B-cell lymphoma. Seminars in hematology. 2008 Review GET IT
Times cited: 22
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 100
New monoclonal antibodies for non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Review GET IT
Times cited: 5
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Clinical advances in hematology & oncology : H&O. 2008 Review GET IT
Times cited: 7
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 Academic Article GET IT
Times cited: 59
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 15
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in hematology. 2008 Review GET IT
Times cited: 16
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 66
Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS patient care and STDs. 2008 Review GET IT
Times cited: 19
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 35
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2007 Academic Article GET IT
Times cited: 154
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 55
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2007 Academic Article GET IT
Times cited: 164
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 106
Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Review GET IT
Times cited: 11
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. British journal of haematology. 2007 Academic Article GET IT
Times cited: 82
Combination treatment approaches and novel therapies for lymphoma. Clinical advances in hematology & oncology : H&O. 2007 Review GET IT
Times cited: 2
Targeted therapies for non-Hodgkin lymphoma: rationally designed combinations. Clinical lymphoma & myeloma. 2007 Review GET IT
Times cited: 4
IL-4 as therapy for non-Hodgkin's lymphoma: possibilities but major challenges. Leukemia & lymphoma. 2007 Comment GET IT
Times cited: 1
Novel therapeutic targets in mantle cell lymphoma. Expert opinion on therapeutic targets. 2007 Review GET IT
Times cited: 4
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma. Biologics : targets & therapy. 2007 Academic Article GET IT
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene. 2007 Review GET IT
Times cited: 86
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. 2007 GET IT
Times cited: 21
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 115
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 11
Therapy for older patients with diffuse large cell lymphoma: targeting the treatment to the patient. Leukemia & lymphoma. 2007 Editorial Article GET IT
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 97
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006 Academic Article GET IT
Times cited: 167
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 68
Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data. Clinical lymphoma & myeloma. 2006 Review GET IT
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 651
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. International journal of cancer. 2006 Review GET IT
Times cited: 52
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2006 Academic Article GET IT
Times cited: 10
B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder. Arthritis and rheumatism. 2006 Letter GET IT
Times cited: 4
Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clinical lymphoma & myeloma. 2006 Academic Article GET IT
Times cited: 20
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 83
New antibodies in the treatment of lymphoma. Clinical advances in hematology & oncology : H&O. 2006 Article GET IT
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006 Academic Article GET IT
Times cited: 34
Mantle cell lymphoma: current concept in biology and treatment. Cancer treatment and research. 2006 Review GET IT
Times cited: 6
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Cancer treatment and research. 2006 Review GET IT
Times cited: 3
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 87
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 217
New developments in immunotherapy for non-Hodgkin's lymphoma. Current oncology reports. 2005 Review GET IT
Times cited: 10
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 145
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 147
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 167
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005 Academic Article GET IT
Times cited: 155
Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology. American Society of Hematology. Education Program. 2005 Academic Article GET IT
Times cited: 20
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 133
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 205
Epratuzumab in non-Hodgkin's lymphomas. Current treatment options in oncology. 2004 Review GET IT
Times cited: 14
Antibodies in the treatment of lymphoma. Clinical advances in hematology & oncology : H&O. 2004 Academic Article GET IT
Times cited: 1
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British journal of haematology. 2004 Academic Article GET IT
Times cited: 305
The role of FDG-PET imaging in the management of lymphoma. Clinical advances in hematology & oncology : H&O. 2004 Review GET IT
Times cited: 29
Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support. Current hematology reports. 2003 Academic Article GET IT
Hodgkin's lymphoma in HIV: unusual presentations and improving outcomes. Clinical advances in hematology & oncology : H&O. 2003 Comment GET IT
Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. Cellular immunology. 2003 Academic Article GET IT
Times cited: 20
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 196
Epratuzumab: targeting B-cell malignancies through CD22. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Review GET IT
Times cited: 53
CD22-directed monoclonal antibody therapy for lymphoma. Seminars in oncology. 2003 Review GET IT
Times cited: 23
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 237
Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer investigation. 2003 Review GET IT
Times cited: 15
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Seminars in oncology. 2003 Academic Article GET IT
Times cited: 53
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 2003 Review GET IT
Times cited: 77
Is daily mvi required in patients receiving parenteral nutrition?. International journal of clinical practice. 2002 Academic Article GET IT
Times cited: 4
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 64
Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood. 2002 Academic Article GET IT
Times cited: 65
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2002 Academic Article GET IT
Times cited: 352
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (New York, N.Y. : 1994). 2002 Academic Article GET IT
Times cited: 254
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002 Academic Article GET IT
Times cited: 199
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Seminars in oncology. 2002 Review GET IT
Times cited: 72
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Seminars in oncology. 2002 Academic Article GET IT
Times cited: 72
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 543
Biology and management of mantle cell lymphoma. Current opinion in oncology. 2001 Review GET IT
Times cited: 49
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). European journal of haematology. Supplementum. 2001 Academic Article GET IT
Times cited: 16
Interleukin-12 gene therapy vaccines: directing the immune system against minimal residual leukemia. Leukemia & lymphoma. 2001 Review GET IT
Times cited: 5
The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. Blood. 2001 Academic Article GET IT
Times cited: 34
Immunotherapy of Non-Hodgkin's lymphomas. Hematology. American Society of Hematology. Education Program. 2001 Review GET IT
Times cited: 99
Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. International journal of radiation oncology, biology, physics. 2000 Academic Article GET IT
Times cited: 3
Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood. 1999 Academic Article GET IT
Times cited: 59
Primary non-Hodgkin's lymphoma of bone. Cancer investigation. 1998 Editorial Article GET IT
Times cited: 1
Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Human gene therapy. 1998 Academic Article GET IT
Times cited: 22
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997 Academic Article GET IT
Times cited: 744
Gene therapy--the challenge for the future. Annals of oncology : official journal of the European Society for Medical Oncology. 1996 Academic Article GET IT
Times cited: 2
Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. The Journal of experimental medicine. 1995 Academic Article GET IT
Times cited: 529

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

BRIDGE (Blood cancer Research Initiative Developing Greater Engagement) with Community Patients awarded by Leukemia & Lymphoma Society, Inc. Principal Investigator 2021 - 2026
A Phase I Trial of Tazemetostat Combined with Venetoclax in Patients with Relapsed/Refractory NHL awarded by Lymphoma Research Foundation Principal Investigator 2021 - 2023

Targeting Unmet Needs For B-cell Lymphomas awarded by Leukemia & Lymphoma Society, Inc. Co-Investigator 2022 - 2027
Mechanism-Based Targeting of Mantle Cell Lymphoma awarded by National Cancer Institute Co-Investigator 2018 - 2024
Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistance awarded by Leukemia & Lymphoma Society, Inc. Co-Investigator 2018 - 2023

Vitamin D and Follicular Lymphoma awarded by National Cancer Institute Principal Investigator Subaward 2017 - 2023

more ...

less ...

Background

education and training

M.D., University of Virginia School of Medicine 1990
B.A., The Johns Hopkins University 1986

Contact

full name

John P Leonard

primary email

jpleonar@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

John P Leonard Senior Associate Dean for Innovation and Initiatives

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage